Miracell Receives FDA 510(k) Clearance for SMART M-CELL Stem Cell Extraction System
核心洞察
Miracell (搜索) secured U.S. FDA 510(k) clearance for its SMART M-CELL (搜索) stem cell extraction system and dedicated kits, marking the first FDA-cleared Efficient Growth Factors extraction system from Korea.
The system demonstrated substantial equivalence to SmartPReP (搜索), a Harvard Medical School-developed standard, with clinical evidence showing pain reduction and functional improvements in knee osteoarthritis and rotator cuff tears.
SMART M-CELL (搜索) is an automated system that concentrates growth factors from blood and bone marrow while maintaining high cell viability and recovery rates for regenerative medicine applications.
Miracell (搜索), a leading stem cell technology company, has obtained U.S. FDA 510(k) clearance for its stem cell extraction system, SMART M-CELL (搜索), along with its dedicated BSC Blood Kit (搜索) and BMSC Bone Marrow Kit (搜索). This milestone makes SMART M-CELL the first FDA-cleared Efficient Growth Factors extraction system from Korea, positioning the company for significant global market expansion.
FDA Clearance Based on Harvard Standard
The clearance was granted based on demonstrated substantial equivalence to SmartPReP (搜索), a globally recognized standard system originally developed by the Institute for Immunological Research (IDI) at Harvard Medical School. This validation underscores the international credibility of Miracell (搜索)'s technology in terms of cell quality and performance.
The cell concentration technology utilizing SmartPrep (搜索) has been continuously validated through extensive research, with approximately 100 related publications and review articles reported to date. Clinical evidence demonstrates significant therapeutic benefits across multiple indications.
Clinical Evidence and Applications
In patients with knee osteoarthritis, BMAC (搜索) (bone marrow aspirate concentrate) injections have demonstrated reductions in pain and improvements in function. For rotator cuff tears, the application of BMAC and BSC (搜索) (blood stem cell concentrate) has been associated with increased cell proliferation, as well as pain relief and functional recovery. Studies in cartilage defects and bone injury sites have reported tissue regeneration and histological improvements following the use of BMAC or BSC.
Beyond musculoskeletal indications, the biological efficacy and broader applicability of cell concentration technologies have been explored across multiple therapeutic areas, including skin regeneration and aesthetics, diabetic ulcers, chronic wound healing, vascular and cardiovascular regeneration, and immune-related conditions.
Advanced Technology and Engineering
SMART M-CELL (搜索) is an automated system that selectively separates and concentrates Efficient Growth Factors from blood and bone marrow. Beyond Efficient Growth Factors, it produces a multi-cell composition that includes growth factors, white blood cells, and SDF-1α (搜索), supporting tissue regeneration and functional recovery. The system is designed to maximize clinical applicability with high recovery rates and operational stability.
Miracell (搜索)'s technology maximizes cellular activity during the extraction process, maintaining cell viability through hundreds of experimental iterations. The company emphasized that as cell purity increases, performance improves exponentially, noting that this FDA clearance reflects the culmination of its intensive R&D efforts to enhance purity—even by just 1%.
Regulatory Distinction and Patent Protection
The FDA clearance validates not only individual components but the entire integrated system—combining both centrifuge and kit—demonstrating its performance and effectiveness as a unified solution. This distinguishes Miracell (搜索) from conventional centrifuge devices, which have typically been classified as lower-risk, notification-only products.
Miracell (搜索) previously secured a U.S. patent in February 2024 for its centrifuge container (kit) used in SMART M-CELL (搜索). The FDA clearance, along with U.S. patent recognition, validates Miracell's differentiated approach from Harvard-based systems and confirms its superior extraction performance and product stability.
Global Market Expansion
Miracell (搜索) has already obtained regulatory approvals in multiple countries and is currently supplying SMART M-CELL (搜索) and related kits to approximately 40 countries worldwide, including across Europe. The company noted that regulatory approvals are underway in markets such as Brazil and Taiwan, and following the recent FDA clearance, it plans to aggressively expand into the global market, including the United States.
Company Portfolio and Future Development
Miracell (搜索) is a regenerative medicine company that has successfully been awarded four stem cell-based new medical technologies in Korea, including treatments for cartilage defects, acute myocardial infarction, critical limb ischemia, and knee osteoarthritis. The company is also advancing efforts to expand its treatment portfolio, including the registration of a new medical technology involving concentrated autologous bone marrow stem cell injections for intervertebral disc pain.
The FDA clearance represents a significant shift toward biologic therapies based on the body's intrinsic healing capabilities, moving away from traditional symptom relief through pharmacological approaches toward fundamental tissue repair and functional restoration.